Plasma miRNAs and Treatment Failure in Participants in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 38153877.
- Also identified by DOI 10.2337/dc23-1540 and PMC identifier 10909680.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To identify plasma miRNAs related to treatment failure in youth with type 2 diabetes (T2D). We examined whether a panel of miRNAs could predict treatment failure in training/test data sets among participants in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study (N = 209). We also examined whether individual miRNAs were associated with treatment failure. Participants were age 14.5 years, and 62% were female. A panel of miRNAs did not predict treatment failure. However, for each doubling, miR-4306 was associated with a 12% decrease (P = 0.040) and miR-483-3p was marginally associated with a 12% increase (P = 0.080) in failure independently of sex, race/ethnicity, BMI, Tanner stage, HbA1c, maternal diabetes, oral disposition index, and treatment arm. The addition of both miRNAs improved model fit (log likelihood without vs. with miRNAs -360.3 vs. -363.5; P = 0.040). miR-483-3p and miR-4306 may be associated with treatment failure in youth with T2D.
Medical subject headings
- Diabetes Mellitus, Type 2
- MicroRNAs
- Diabetes, Gestational